Timing of futility analyses for 'proof of concept' trials

Statistics in Medicine

Volumn 24, Issue 12, 2005, Pages 1815-1835

  Gould, A Lawrence ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bayesian; Cost; Decision; Group sequential; Predictive power; Sample size

Indexed keywords

ARTICLE; CALCULATION; CLINICAL RESEARCH; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECISION MAKING; HUMAN; HYPOTHESIS; INFORMATION PROCESSING; OUTCOMES RESEARCH; PREDICTION; PROBABILITY; RESOURCE ALLOCATION; SAMPLE SIZE; STATISTICAL ANALYSIS;

BAYES THEOREM; CLINICAL TRIALS; HUMANS; MEDICAL FUTILITY; MODELS, STATISTICAL; UNITED STATES; WITHHOLDING TREATMENT;

EID: 21044448277     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2087     Document Type: Article

References (17)

1. Whitehead J, Matsushita T. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Statistics in Medicine 2003; 22:677-687.
2. Wang YG, Leung DH-Y. Conditional probability of significance for early stopping in favor of $H_0$. Sequential Analysis 2002; 21:145-160.
3. Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979; 35: 775-783.
4. Spiegelhalter D, Freedman D, Blackburn P. Monitoring clinical trials: conditional or predictive power? Controlled Clinical Trials 1980; 7:8-17.
5. Blackwelder WC. Proving the null hypothesis in clinical trials. Controlled Clinical Trials 1982; 3:345-353.
6. Pallay A. On the timing of a futility analysis in clinical trials. Journal of Biopharmaceutical Statistics 2000; 10:399-405.
7. Aitchison J, Dunsmore IR. Statistical Prediction Analysis. Cambridge University Press: New York, 1975.
8. Turnbull, BW. Stochastic curtailment. Encyclopedia of Statistical Sciences. Wiley: New York, Chichester, 1997; 521-523.
9. Spiegelhalter DJ, Thomas A, Best NG, Gilks WR. WinBugs Version 1.4 MRC Biostatistics Unit. Institute of Public Health, 2002.
10. Adcock CJ. Sample size determination: a review. The Statistician 1997; 46:261-283.
11. Enas GG, Donseif BE, Sampson CB, Rockhold FW et al. Monitoring vs interim analyses of clinical trials: a perspective from the pharmaceutical industry. Controlled Clinical Trials 1989; 10:57-70.
12. Fleming TR, DeMets DL. Monitoring of clinical trials: issues and recommendations. Controlled Clinical Trials 1993; 14:183-197.
13. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers - are we being naive? Journal of Infectious Diseases 1997; 175:237-246.
14. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125:605-613.
15. Fleming TR. Surrogate end points in cardiovascular disease trials. American Heart Journal 2000; 139: S193-S196.
16. Goodman SN. A comment on replication, p-values, and evidence. Statistics in Medicine 1992; 11:875-879.
17. Hung HMJ, O'Neill RT, Bauer P, Köhne K. The behavior of the p-value when the alternative hypothesis is true. Biometrics 1997; 53:11-22.